AIM: To determine the short-term cost-utility of molecular adsorbent recirculating system (MARS) treatment in acute liver failure (ALF). METHODS: A controlled retrospective study was conducted with 90 ALF patients treated with MARS from 2001 to 2005. Comparisons were made with a historical control group of 17 ALF patients treated from 2000 to 2001 in the same intensive care unit (ICU) specializing in liver diseases. The 3-year outcomes and number of liver transplantations were recorded. All direct liver disease-related medical expenses from 6 mo before to 3 years after ICU treatment were determined for 31 MARS patients and 16 control patients. The health-related quality of life (HRQoL) before MARS treatment was estimated by a panel of ICU doctors and after MARS using a mailed 15D (15-dimensional generic health-related quality of life instrument) questionnaire. The HRQoL, cost, and survival data were combined and the incremental cost/quality-adjusted life years (QALYs) was calculated. RESULTS: In surviving ALF patients, the health-related quality of life after treatment was generally high and comparable to the age- and gender-matched general Finnish population. Compared to the controls, the average cost per QALY was considerably lower in the MARS group (64,732 euros vs 133,858 euros) within a timeframe of 3.5 years. The incremental cost of standard medical treatment alone compared to MARS was 10,928 euros, and the incremental number of QALYs gained by MARS was 0.66. CONCLUSION: MARS treatment combined with standard medical treatment for ALF in an ICU setting is more cost-effective than standard medical treatment alone.
AIM: To determine the short-term cost-utility of molecular adsorbent recirculating system (MARS) treatment in acute liver failure (ALF). METHODS: A controlled retrospective study was conducted with 90 ALFpatients treated with MARS from 2001 to 2005. Comparisons were made with a historical control group of 17 ALFpatients treated from 2000 to 2001 in the same intensive care unit (ICU) specializing in liver diseases. The 3-year outcomes and number of liver transplantations were recorded. All direct liver disease-related medical expenses from 6 mo before to 3 years after ICU treatment were determined for 31 MARS patients and 16 control patients. The health-related quality of life (HRQoL) before MARS treatment was estimated by a panel of ICU doctors and after MARS using a mailed 15D (15-dimensional generic health-related quality of life instrument) questionnaire. The HRQoL, cost, and survival data were combined and the incremental cost/quality-adjusted life years (QALYs) was calculated. RESULTS: In surviving ALFpatients, the health-related quality of life after treatment was generally high and comparable to the age- and gender-matched general Finnish population. Compared to the controls, the average cost per QALY was considerably lower in the MARS group (64,732 euros vs 133,858 euros) within a timeframe of 3.5 years. The incremental cost of standard medical treatment alone compared to MARS was 10,928 euros, and the incremental number of QALYs gained by MARS was 0.66. CONCLUSION: MARS treatment combined with standard medical treatment for ALF in an ICU setting is more cost-effective than standard medical treatment alone.
Authors: F Pugliese; G Novelli; L Poli; G B Levi Sandri; G Di Folco; S Ferretti; V Morabito; F Ruberto; P B Berloco Journal: Transplant Proc Date: 2008 Jul-Aug Impact factor: 1.066
Authors: Taru Kantola; Anna Maria Koivusalo; Satu Parmanen; Krister Höckerstedt; Helena Isoniemi Journal: World J Gastroenterol Date: 2009-06-28 Impact factor: 5.742
Authors: Zhi Qu; Christian Krauth; Volker Eric Amelung; Alexander Kaltenborn; Jill Gwiasda; Lena Harries; Jan Beneke; Harald Schrem; Sebastian Liersch Journal: World J Hepatol Date: 2018-11-27
Authors: Arielle Cimeno; Samuel Sultan; Josue Alvarez-Casas; Steven I Hanish; David A Bruno; William R Hutson; Deborah M Stein; Thomas M Scalea; Rolf N Barth; John C LaMattina Journal: Transplant Direct Date: 2021-02-18